DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months.

Author(s): Knuf M, Zepp F, Meyer CU, Habermehl P, Maurer L, Burow HM, Behre U, Janssens M, Willems P, Bisanz H, Vetter V, Schmidt-Ott R

Affiliation(s): Children's Hospital, Dr. Horst Schmidt Klinik, Ludwig-Erhard-Str. 100, Wiesbaden 65199, Germany. Markus.Knuf@hsk-wiesbaden.de

Publication date & source: 2010-08, Eur J Pediatr., 169(8):925-33. Epub 2010 Feb 11.

Publication type: Research Support, Non-U.S. Gov't

This study compared intramuscular and subcutaneous administration of two doses of measles-mumps-rubella-varicella (MMRV) combination vaccine (Priorix-Tetra, GlaxoSmithKline Biologicals) in children. Healthy children (N = 328) were randomised to receive MMRV either intramuscularly or subcutaneously. Reactogenicity was similar between treatment groups for immediate vaccination pain, vaccination site pain, redness and incidence of fever and rashes. Slightly less vaccination site swelling occurred during days 0-3 of the post-vaccination period after intramuscular administration. Seroconversion rates for all components, 42-56 days post-dose 2, ranged from 99.3% to 100% in the intramuscular group and from 98.6% to 100% in the subcutaneous. Cell-mediated immunity data supported the humoral immunogenicity findings. In summary, the MMRV vaccine is well tolerated and highly immunogenic when administered either subcutaneously or intramuscularly to children in the second year of life.

Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017